To safely manage patients presenting with 7-hydroxymitragynine (7-OH) physical dependence, clinical risk-screening requires identifying vulnerable patient populations and characterizing their exposure 1, 2\. Because 7-OH is a potent mu-opioid receptor agonist, abrupt loss of retail access can trigger severe acute withdrawal, making early triage vital 1, 3, 4\.  
The primary clinical risk-screening criteria, clinical triage steps, and structured screening questions are detailed below.

### 1\. High-Risk Patient Screening Criteria

Patients meeting any of the following criteria should **never be advised to "white-knuckle" withdrawal** and require immediate, structured clinical triage 5:

* **High Daily Dose or Hourly Redosing**: Patients using high daily doses or requiring frequent, hourly redosing to prevent withdrawal 1, 6\. These patterns are associated with rapid physical dependence and severe, acute interdose withdrawal 1\.  
* **Vulnerable Populations**: Patients with **cardiac disease, frailty, pregnancy, or very young or older age** 1, 6\. Autonomic stress and severe dehydration from withdrawal-related gastrointestinal hypermotility (such as vomiting and diarrhea) present higher physiological risks in these populations 1, 7\.  
* **Neurological Comorbidities**: Patients with a history of **seizure disorders or severe insomnia**, as withdrawal severely lowers the seizure/safety threshold 1, 6\.  
* **Polysubstance Use**: Active concurrent use of alcohol, benzodiazepines, stimulants, fentanyl, gabapentinoids, or nicotine 5, 6\. Combining 7-OH with other central nervous system depressants significantly elevates the risk of severe respiratory depression and fatal overdose 8, 9\.  
* **Complex Medication Metabolism**: Concomitant use of medications that alter drug metabolism (such as CYP inhibitors or inducers), sedatives, serotonergic agents, or adrenergic agents, which can complicate buprenorphine initiation, alter autonomic stability, or increase sedation risks 5, 6\.  
* **Psychiatric and Social Vulnerability**: Unstable psychiatric illness, unstable housing, or a low tolerance for prolonged withdrawal, which substantially increases the risk of impulsive substitution with high-risk illicit opioids like fentanyl 5, 6\.

### 2\. The Five-Step Clinical Intake Algorithm

When screening a patient, clinicians should follow a structured five-step triage sequence to match the patient to the correct treatment setting 2, 5:

1. **Define Exposure**: Document the product type (such as tablets, shots, gummies, or films), labeled milligrams, actual daily units consumed, redosing frequency, route of administration, duration of use, and cost per day 2, 10\.  
2. **Determine Dependence Severity**: Evaluate features of severe substance use disorder, including failed quit attempts, interdose withdrawal symptoms, level of impairment, compulsive use patterns, and intense cravings 2, 10\.  
3. **Risk Stratify**: Check for medical comorbidities, seizure or cardiac risk, pregnancy, psychiatric instability, polysubstance use, and complex medication interactions 2\.  
4. **Match Treatment Setting**: Based on risk stratification, determine the safest treatment pathway: a slow outpatient taper, standard buprenorphine-naloxone induction, low-dose buprenorphine microinduction (to bypass precipitated withdrawal risk), or high-level inpatient detoxification 2, 11\.  
5. **Prevent Substitution**: Actively counsel the patient on fentanyl risks, provide a prescription/kit for rescue naloxone, establish a rapid outpatient follow-up interval, and involve family or caregiver support when appropriate 5, 12, 13\.

### 3\. Practical Screening Questions for Clinicians

Because patients often conceptualize 7-OH as a "natural supplement" rather than an opioid, they are unlikely to volunteer their use unless asked directly using familiar retail brand names 14, 15\. Clinicians should separate questions about natural kratom leaf from concentrated 7-OH products and ask 14, 16:

* *"Do you use kratom, 7-OH, 7-hydroxy, or brand-name retail products like Press'd, 7OHMZ, or Hydroxie? Do you buy tablets, shots, gummies, or sublingual films from smoke shops, gas stations, or online?"* 12, 14  
* *"How many milligrams or units do you take per day, and how soon after a dose do you begin to feel physical withdrawal symptoms like sweating, restlessness, chills, or nausea?"* 10, 14, 17  
* *"What happens if you miss a dose or try to go a full day without it? Have you tried to stop in the past, and if so, what symptoms made the attempt fail?"* 10, 14  
* *"Would you consider purchasing fentanyl, illicit street pills, or other non-prescribed opioids if your retail store suddenly ran out of 7-OH tomorrow?"* 10, 14  
* *"Do you currently have access to naloxone (Narcan), and does someone living near you know how to administer it to reverse an overdose?"* 14, 18

📊 Since we just finalized the clinical intake protocol, would you like me to extract a concise, printable one-page "Clinical Screening Checklist" containing these exact intake questions and high-risk markers to keep on hand at your clinic?